144 Participants Needed

Hormonal Contraceptives for Depression

(CHARM Trial)

AM
Overseen ByAndrew M Novick, MD PhD
Prior Safety DataThis treatment has passed at least one previous human trial
Approved in 5 JurisdictionsThis treatment is already approved in other countries

Trial Summary

Will I have to stop taking my current medications?

The trial requires that participants do not currently use hormonal contraceptives or medications that affect sex hormones. Additionally, participants cannot be on psychotropic medications. If you are taking these types of medications, you may need to stop them to participate.

What data supports the effectiveness of the drug Levonorgestrel/ethinyl estradiol for depression?

The research suggests that hormonal contraceptives, including those containing ethinyl estradiol, may be linked to mood changes and depression in some women. However, there is no clear consensus or strong evidence supporting their effectiveness for treating depression, and more research is needed to understand their impact on mood disorders.12345

Is hormonal contraception generally safe for humans?

Hormonal contraceptives are widely used, but they can cause mood changes, including depression, in some people. Some studies suggest a link between contraceptive use and increased risk of depression and suicide, especially in adolescents, but the evidence is not conclusive. It's important to monitor mood changes when using these contraceptives.14678

How does the drug Levonorgestrel/ethinyl estradiol differ from other treatments for depression?

Levonorgestrel/ethinyl estradiol is primarily a hormonal contraceptive, and its use for depression is unique because it involves hormones that can affect mood. Unlike traditional antidepressants, this drug's impact on depression may be linked to its hormonal components, which can sometimes worsen mood in some users, highlighting the need for careful consideration of its effects on mental health.145910

What is the purpose of this trial?

Purpose of this study: The purpose of this study is to learn more about how hormonal oral contraceptives affect brain processes and emotional wellbeing.Procedures: If participants agree to participate, the following will happen:1. Eligibility visit (remote screening session)2. If participants are eligible to participate in the study, they will be placed in one of two groups. If they are in the first group, they will be asked to take an oral contraception pill ("study drug") every day for 21 days. If they are in the second, they will take a placebo every day for 21 days. A placebo is a pill that looks like medicine but is not real and will have no medical effect on participants. Participants will not get to choose which group they are in, nor will they be told which group they are in.3. During the three-week period in which participants will take either the study drug or placebo, they will be asked to complete daily check-in surveys on their computer or mobile device.4. Participants will be asked to attend two additional visits over the course of about three weeks. At these visits, participants will be asked to undergo a urine drug screen, a blood draw, and a magnetic resonance imaging (MRI). They will also be asked to complete behavioral questionnaires.

Research Team

AM

Andrew M Novick, MD PhD

Principal Investigator

University of Colorado Denver Anschutz Medical Campus

Eligibility Criteria

The CHARM Study is for right-handed females aged 18+, with regular menstrual cycles and good health. Participants must not smoke, have a history of severe disorders, or use hormonal contraceptives recently. They should be willing to avoid intercourse or use non-hormonal contraception during the study.

Inclusion Criteria

In generally good health per self-report. Those with a chronic medical condition may participate at the discretion of the principal investigator if the condition is stable
For those wishing to complete study screening session remotely: access to a reliable internet connection, computer to complete electronic consent and a private space to complete the session
Access to a reliable internet connection or cell phone data to complete daily questionnaires
See 6 more

Exclusion Criteria

Metal in body unsafe for magnetic resonance imaging
I have irregular menstrual cycles.
Presence or history of severe or unstable physical, neurological (per health history interview) or psychiatric disorders (assessed by Miniature International Neuropsychiatric Interview (MINI) but per Diagnostic and Statistical Manual of Mental Disorders - fifth edition (DSM-V) criteria, and the discretion of the principal investigator)
See 18 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1 week
1 visit (remote)

Treatment

Participants take either an oral contraceptive or placebo daily for 21 days and complete daily check-in surveys

3 weeks
2 visits (in-person)

Follow-up

Participants are monitored for changes in sexual function, anhedonia, and neural activity after treatment

3 weeks

Treatment Details

Interventions

  • Levonorgestrel/ethinyl estradiol
  • Placebo
Trial Overview This trial tests how oral contraceptives affect brain activity and mood. Participants will take either an oral contraceptive pill or a placebo daily for three weeks while completing surveys and undergoing MRI scans, urine tests, blood draws, and questionnaires.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: Levonorgestrel/ethinyl estradiolExperimental Treatment1 Intervention
Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg - once a day for 21 days
Group II: PlaceboPlacebo Group1 Intervention
Placebo once a day for 21 days

Levonorgestrel/ethinyl estradiol is already approved in European Union, United States, Canada, Japan for the following indications:

๐Ÿ‡ช๐Ÿ‡บ
Approved in European Union as Levonorgestrel/ethinyl estradiol for:
  • Contraception
  • Menstrual regulation
  • Premenstrual dysphoric disorder
๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as Levonorgestrel/ethinyl estradiol for:
  • Contraception
  • Premenstrual dysphoric disorder
  • Acne vulgaris
๐Ÿ‡จ๐Ÿ‡ฆ
Approved in Canada as Levonorgestrel/ethinyl estradiol for:
  • Contraception
  • Menstrual regulation
  • Premenstrual dysphoric disorder
๐Ÿ‡ฏ๐Ÿ‡ต
Approved in Japan as Levonorgestrel/ethinyl estradiol for:
  • Contraception
  • Menstrual regulation

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials
1,842
Recruited
3,028,000+

Findings from Research

Hormonal contraception, particularly older oral contraceptive pills containing ethinylestradiol, can trigger or worsen depression in some individuals due to the type and amount of progestogen they contain.
Newer oral contraceptive pills that use physiological forms of estrogen may have a lower risk of causing mood problems, suggesting that clinicians should carefully evaluate the relationship between hormonal contraception use and mood changes in patients.
Hormonal contraception and mood disorders.Mu, E., Kulkarni, J.[2022]
Hormonal treatments, particularly transdermal estrogens, can effectively manage premenstrual, postnatal, and climacteric depression by stabilizing hormonal fluctuations and enhancing mood, yet this approach is often overlooked by psychiatrists.
The treatment may also include testosterone for improved mood and energy, but caution is needed with progestogen due to potential intolerance; careful patient history is essential to avoid misdiagnosis of hormone-responsive depression.
A guide to the treatment of depression in women by estrogens.Studd, JW.[2022]
Women with major depressive disorder (MDD) using combined estrogen-progestin contraceptives reported significantly lower depression severity and better physical functioning compared to those not using hormonal treatment, based on data from the STAR*D study involving 1,338 female outpatients.
In contrast, women using progestin-only contraceptives experienced more general medical comorbidities and worse physical functioning, highlighting the differing impacts of hormonal contraceptives on mood and health in women with MDD.
Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression.Young, EA., Kornstein, SG., Harvey, AT., et al.[2019]

References

Hormonal contraception and mood disorders. [2022]
A guide to the treatment of depression in women by estrogens. [2022]
Influences of hormone-based contraception on depressive symptoms in premenopausal women with major depression. [2019]
EFFECT OF HORMONAL CONTRACEPTION ON DEPRESSION IN WOMEN. [2023]
A double-blind randomised placebo controlled trial of postnatal norethisterone enanthate: the effect on postnatal depression and serum hormones. [2022]
A comparison of cycle control with monophasic levonorgestrel/ethinylestradiol 100 micrograms/20 micrograms versus triphasic norethindrone/ethinylestradiol 500-750-1000 micrograms/35 micrograms: a multicenter, randomized, open-label study. [2019]
New hormonal contraceptives: a comprehensive review of the literature. [2019]
[Hormonal contraceptive use, depression and suicide]. [2021]
[New forms of hormonal contraception]. [2014]
Hormonal Contraception Use and Depression Among Women in Saudi Arabia. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity